Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01732107 · ClinicalTrials.gov registry record · Phase 2
Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
A Phase 2 study, sponsored by Noah Hahn, M.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01732107 is a Phase 2 study that was terminated before completion, run by Noah Hahn, M.D.. The registered enrollment target is 13 participants.
The verdict
NCT01732107, a Phase 2 study, was terminated before completion, sponsored by Noah Hahn, M.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This trial will assess the 6-month complete response rate and toxicity profile of oral dovitinib therapy in BCG-refractory urothelial carcinoma patients with tumors with FGFR3 mutations or over-expression who are ineligible for or refusing cystectomy.
Interventions
- DRUG Dovitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-03 |
| Est. Completion | 2017-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01732107
The ClinicalTrials.gov registry entry for NCT01732107 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noah Hahn, M.D., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dovitinib is the first listed.
NCT01732107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01732107 about?
NCT01732107 is a clinical study titled "Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression". This trial will assess the 6-month complete response rate and toxicity profile of oral dovitinib therapy in BCG-refractory urothelial carcinoma patients with tumors with FGFR3 mutations or over-expression who are ineligible for or refusing cystectomy.
What is the current status of trial NCT01732107?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2013-03. Estimated completion is 2017-03-06.
What interventions are being tested in trial NCT01732107?
The interventions under investigation include: Dovitinib (DRUG).
Who is sponsoring clinical trial NCT01732107?
This trial is sponsored by Noah Hahn, M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.